Duncan joined Cancer Research UK as a policy adviser in October 2017. He leads the charity's policy and influencing work on patient access to cancer medicines, including the impact of Brexit and drug pricing. Before joining CRUK, Duncan studied politics and economics at the University of Oxford, then worked at public policy think tank ResPublica.
A new breed of targeted cancer drug has been approved for NHS use in England. But drugs like larotrectinib also pose unique and complex challenges for the NHS, which have been exacerbated by the COVID-19 pandemic.
NHS England announced plans to fast track “revolutionary” new cancer drugs. But there’s still some way to go before these drugs might reach patients.
With NHS budgets stretched, it’s critical that cancer drugs offer value for money. We’ve teamed up with the Greater Manchester Health and Social Care Partnership to investigate a different approach to drug pricing.
A revamped Cancer Drugs Fund is giving patients new options and renewed chances of successful treatment, quicker than ever before.
With two complex CAR T immunotherapies now approved on the NHS in England, we look at how the health service has had to react to these exciting new treatments.